伊曲康唑与venglustat药物相互作用研究及PBPK模型预测CYP3A抑制剂的影响
本研究通过开放标签、单序列、两周期DDI试验,在健康受试者中评估伊曲康唑对venglustat暴露的影响,并建立PBPK模型预测其他CYP3A抑制剂的作用。结果显示伊曲康唑使venglustat AUC增加2.03倍(90%CI 1.81-2.27),模型预测强、中、弱CYP3A抑制剂分别使稳态AUC增加1.74、1.52、1.08倍。
要点
- 伊曲康唑使venglustat AUC增加2.03倍(90%CI 1.81-2.27)。
- PBPK模型预测克拉霉素、氟康唑、氟伏沙明和西咪替丁对venglustat暴露的影响。
- 结果有助于理解venglustat的DDI潜力并指导合并用药剂量建议。
核心结论
- 伊曲康唑对venglustat暴露的影响已在临床中量化,PBPK模型成功建立、验证并用于评估其他CYP3A抑制剂的DDI效应。
研究设计与样本
- 开放标签、单序列、两周期DDI研究在健康受试者中进行,多次每日两次口服100 mg伊曲康唑与单次15 mg venglustat合用。
- 使用理化、体外和体内药代动力学数据建立简化PBPK模型,并用包括伊曲康唑DDI研究在内的venglustat临床研究数据验证。
主要发现
- 合用伊曲康唑使venglustat浓度-时间曲线下面积增加2.03倍(90%CI:1.81-2.27)。
- 预测强CYP3A抑制剂(克拉霉素)使venglustat稳态AUC增加1.74倍(5th-95th百分位:1.30-2.49)。
- 预测中等CYP3A抑制剂(氟康唑)使venglustat稳态AUC增加1.52倍(1.23-1.88)。
- 预测弱CYP3A抑制剂(氟伏沙明和西咪替丁;关闭CYP2D6抑制)使venglustat稳态AUC分别增加1.08倍(1.03-1.15)和1.08倍(1.04-1.12)。
临床怎么用
- 临床合用时需考虑CYP3A抑制剂对venglustat暴露的增加效应,尤其是强和中效抑制剂。
- PBPK模型预测结果可辅助制定venglustat与不同强度CYP3A抑制剂合用的剂量建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Venglustat is an oral glucosylceramide synthase inhibitor under clinical investigation to treat various lysosomal storage diseases. Metabolism is a main pathway for its elimination in humans with CYP3A being the major contributor. This study aims to evaluate effect of CYP3A inhibition (using itraconazole) on venglustat exposure and to develop and validate a physiologically based pharmacokinetic (PBPK) model to assess effects of additional CYP3A inhibitors of varying potencies on venglustat pharmacokinetics. METHODS: An open-label, single-sequence, 2-period drug-drug interaction (DDI) study was conducted in healthy subjects with coadministration of multiple twice daily oral doses of 100 mg itraconazole against a single dose of 15 mg venglustat. A minimal PBPK model was developed using available physicochemical, in vitro and in vivo pharmacokinetic data and validated using data from relevant venglustat clinical studies including the itraconazole DDI study. Effects of additional CYP3A inhibitors on venglustat exposure were predicted. RESULTS: Coadministration with itraconazole increased venglustat area under the concentration-time curve by 2.03-fold (90% confidence interval [90%CI]: 1.81-2.27). Venglustat steady-state area under the concentration-time curve during a dosing interval following coadministration with strong (clarithromycin), moderate (fluconazole) and weak (fluvoxamine and cimetidine; with CYP2D6 inhibition turned off) CYP3A inhibitors is predicted to increase by 1.74- (5th-95th centile, 1.30-2.49), 1.52- (1.23-1.88), 1.08- (1.03-1.15) and 1.08-fold (1.04-1.12), respectively. CONCLUSION: The effect of itraconazole on venglustat exposure was quantified clinically, and a minimal PBPK model was successfully developed, validated and applied to assess DDI effect of additional CYP3A inhibitors on venglustat. The results help to further understand the DDI potential with venglustat and will inform dose recommendations with comedications.
引用
- Li L, Zhang YY, Sharma J, et al. Drug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics. Br J Clin Pharmacol. 2025. PMID: 40066762. doi:10.1002/bcp.70037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。